Elicio Therapeutics Reports Results From Randomized Phase 2 AMPLIFY-7P Study Evaluating ELI-002 7P In Patients With Adjuvant mKRAS-Driven Pancreatic Ductal Adenocarcinoma

뉴스 본문을 불러오고 있어요.

Elicio Therapeutics Reports Results From Randomized Phase 2 AMPLIFY-7P Study Evaluating ELI-002 7P In Patients With Adjuvant mKRAS-Driven Pancreatic Ductal Adenocarcinoma | 웨이프 WAPE

Elicio Therapeutics Reports Results From Randomized Phase 2 AMPLIFY-7P Study Evaluating ELI-002 7P In Patients With Adjuvant mKRAS-Driven Pancreatic Ductal Adenocarcinoma

기사 요약

관련 종목

댓글 —